- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Sacituzumab Govitecan Maintains Efficacy Benefit Over Chemo in Metastatic TNBC, Irrespective of Agent
June 7th 2021, 7:05pm
The antibody-drug conjugate sacituzumab govitecan retained benefit in progression-free survival, overall survival, and objective response rate over physician’s choice of therapy, regardless of the chemotherapy agent used.
Pembrolizumab/Axitinib Survival Benefit Sustained in Long-Term Results in RCC
June 7th 2021, 6:50pm
The frontline combination of pembrolizumab plus axitinib continued to show a survival benefit over single-agent sunitinib in patients with renal cell carcinoma.
HRQOL Analysis Further Supports Pembrolizumab/Lenvatinib for Frontline RCC
June 7th 2021, 6:29pm
Frontline treatment with the combination of lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma led to similar health-related quality of life outcomes and disease-related symptom scores vs sunitinib.
SD-101 Plus Pembrolizumab and Paclitaxel Yields Moderate Response Boost in High-Risk, HER2-Negative Breast Cancer
June 7th 2021, 6:19pm
Treatment with intra-tumoral SD-101 in combination with pembrolizumab and paclitaxel resulted in a non-statistically significant increase in estimated pathological complete response rates in patients with high-risk, HER2-negative stage II/III breast cancer across 3 HER2-negative biomarker signature groups.
Prolonged Treatment With Bevacizumab Does Not Yield Further Survival Benefit in Ovarian Cancer
June 7th 2021, 5:19pm
Although prolonged treatment with bevacizumab for up to 30 months is feasible with consistent safety data for patients with primary epithelial ovarian, fallopian tube, or peritoneal cancer, the regimen did not improve survival over the standard 15 month treatment regimen.
Mirvetuximab Soravtansine Plus Bevacizumab May Provide an Effective Non-Platinum Option in Recurrent, Platinum Agnostic Ovarian Cancer
June 7th 2021, 5:01pm
Mirvetuximab soravtansine in combination with bevacizumab yielded durable responses in patients with recurrent, platinum agnostic ovarian cancer, a population in need of more effective, non-platinum treatments.
Larotrectinib Demonstrates Promising Responses in NTRK-Fusion+ CNS Tumors
June 7th 2021, 4:17pm
Larotrectinib has demonstrated efficacious responses and disease control in patients with TRK fusion–positive central nervous system tumors.
Insights in Breast Cancer, GI Malignancies at ASCO 2021: Drs Milind Javle and Erika Hamilton
June 7th 2021, 12:00am
OncLive News Network: On Location at ASCO 2021
OncLive sits down with Erika P. Hamilton, MD, and Milind Javle, MD, on the pivotal studies in breast cancer and gastrointestinal cancers, respectively, at the 2021 ASCO Annual Meeting.
Lenvatinib/Pembrolizumab Yields Continuing Efficacy in Advanced Melanoma
June 6th 2021, 7:49pm
Lenvatinib and pembrolizumab continued to yield meaningful and durable responses in patients with advanced melanoma who had progressed on previous PD-L1 inhibitor treatment.
Lifileucel Continues to Demonstrate Durable Responses in Heavily Pretreated Advanced or Metastatic Melanoma
June 6th 2021, 7:20pm
Lifileucel has demonstrated promising long-term responses in patients with heavily pretreated advanced or metastatic melanoma who have progressed following PD-1 and PD-L1 inhibition.
Nivolumab Alone, With Ipilimumab Maintains Improved Outcomes in Advanced Melanoma in Long-Term Follow-Up
June 6th 2021, 7:10pm
Nivolumab monotherapy, or in combination with ipilimumab, continued to demonstrate durable improvements in overall survival compared with ipilimumab alone in patients with previously untreated advanced melanoma.
Selpercatinib Elicits Encouraging Antitumor Activity in Pediatric RET-Altered Solid Tumors
June 6th 2021, 6:37pm
Selpercatinib demonstrated evidence of preliminary efficacy and safety in pediatric patients with advanced RET-altered solid tumors.
Selpercatinib Improves Responses Regardless of Immediate Prior Treatment in RET-Mutant Medullary Thyroid Cancer
June 6th 2021, 6:35pm
Selpercatinib improved overall response rates in most patients with RET-mutated medullary thyroid cancer irrespective of prior systemic therapy.
Nivolumab Plus Chemotherapy Outperforms Chemotherapy Alone in Resectable NSCLC
June 6th 2021, 6:21pm
Neoadjuvant nivolumab in combination with platinum-doublet chemotherapy significantly improved pathological complete response rates and had a greater depth of pathological response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.
Adjuvant Gefitinib Fails to Outshine Chemo in EGFR+ NSCLC
June 6th 2021, 6:13pm
Adjuvant treatment with gefitinib delayed early relapse in patients with completely resected EGFR-mutant non–small cell lung cancer. However, the EGFR inhibitor did not significantly improve disease-free survival or overall survival compared with cisplatin/vinorelbine.
Ultralow Risk 70-Gene Signature Is Indicative of Excellent Survival Outcomes in Early-Stage Breast Cancer
June 6th 2021, 6:10pm
Patients with early-stage breast cancer who have ultralow risk disease indicated by a 70-gene signature demonstrated have an excellent survival prognosis regardless of clinical risk.
Neoadjuvant Pyrotinib Quadruplet Significantly Improves pCR in HER2+ Breast Cancer
June 6th 2021, 6:07pm
The combination of pyrotinib plus trastuzumab, docetaxel, and carboplatin (TCbH) significantly improved the total pathological complete response rate over TCbH alone in the neoadjuvant treatment of patients with HER2-positive breast cancer.
Neoadjuvant Pertuzumab Plus Trastuzumab/Nab-Paclitaxel Achieves 64% pCR With Less Toxicity in HER2+ Breast Cancer
June 6th 2021, 5:51pm
Pertuzumab plus trastuzumab, and nab-paclitaxel used as neoadjuvant therapy in patients with HER2-positive locally advanced breast cancer induced a pathologic complete response similar to that achieved with docetaxel, carboplatin, trastuzumab, and pertuzumab, with less treatment-related toxicities.
CART-ddBCMA Elicits 100% ORR in Relapsed/Refractory Multiple Myeloma
June 6th 2021, 5:43pm
The autologous CAR T-cell product CART-ddBCMA was found to elicit a 100% objective response rate in patients with relapsed/refractory multiple myeloma, with deep and durable responses noted in those with poor prognostic factors.